Lipopotrein(a): from the complex metabolism to the optimal lowering drug.
In conclusion, Lp(a) is a key determinant of residual cardiovascular risk and a better understanding of its pathophysiology and the development of targeted therapies may improve cardiovascular risk stratification and prevention strategies.
Francesco Di Giacomo Barbagallo, M. Berteotti, G. Bosco et al.
· Internal and Emergency Medic... · 0 citations